The integration of human immunodeficiency virus (HIV) care and family planning services is critical for more than 17.4 million HIV-infected women, of whom nearly 95% live in low- and middle-income countries (LMICs) \[[@CIV1001C1], [@CIV1001C2]\]. These women face an increased risk for complications following an unplanned pregnancy, including the risk of vertical transmission of HIV \[[@CIV1001C3], [@CIV1001C4]\]. Accordingly, the World Health Organization (WHO) recommends the use of long-acting, reversible contraceptive methods for family planning, including progestin-releasing subdermal implants \[[@CIV1001C5]\], and the use of efavirenz-based antiretroviral therapy (ART) as preferred first-line treatment for HIV-1 \[[@CIV1001C6], [@CIV1001C7]\]. Nevirapine-based ART remains an alternative; however, its use is declining due to inferior virologic efficacy and a higher rate of toxicity compared with efavirenz \[[@CIV1001C6], [@CIV1001C8]\]. Despite the benefits of both implantable contraceptives and ART, drug--drug interactions between these recommended therapies represent a critical barrier to effective family planning methods for HIV-infected women.

The levonorgestrel-releasing subdermal implant is widely used in sub-Saharan Africa \[[@CIV1001C9]\]. After insertion, the implant may remain in place for up to 5 years, with a low failure rate of 0.1 pregnancy per 100 woman-years during the first year \[[@CIV1001C10]\]. Levonorgestrel is released from the implant initially at 100 μg/day, decreasing to 40 μg/day within 1 year and to 30 μg/day within 3 years, providing stable daily drug concentrations \[[@CIV1001C10]\]. Levonorgestrel is metabolized via hepatic enzymes, and coadministration of medications that induce or inhibit the cytochrome P450 (CYP) enzyme system influences levonorgestrel exposure \[[@CIV1001C10]\]. The risk for drug--drug interaction compromising contraception efficacy is greatest with antiretrovirals that induce CYP3A4, including efavirenz and nevirapine. Few data characterize the impact of the drug--drug interaction between ART and levonorgestrel. However, when oral levonorgestrel for emergency contraception was combined with efavirenz, levonorgestrel exposure decreased 56%, as measured by the area under the concentration time curve (AUC) in 12 healthy volunteers \[[@CIV1001C11]\]. In contrast, 3 HIV-infected women who received nevirapine-based ART and oral contraceptive pills had higher levonorgestrel exposure compared with 3 HIV-infected participants who did not receive ART (AUC~0--24\ hours~ 147 vs 114 ng h/mL) \[[@CIV1001C12]\]. Further, a retrospective analysis among 570 HIV-infected women who used the levonorgestrel-releasing implant identified concomitant use of efavirenz as the only factor correlated with unintended pregnancy (15 of 16 observed pregnancies occurred in women receiving efavirenz; 12.4% pregnancy rate); no pregnancies occurred among 208 women who received nevirapine \[[@CIV1001C13]\]. There is no known interaction between nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and levonorgestrel \[[@CIV1001C14]\]. No evidence exists regarding the pharmacokinetic effect of ART on levonorgestrel-releasing implants.

Noting the absence of high-quality studies, recent WHO guidance states that women on efavirenz- or nevirapine-based ART can "generally use" subdermal implants, because the benefits of contraception generally outweigh the risks \[[@CIV1001C5], [@CIV1001C15]\]. Our primary objective in this study was to assess the effect of efavirenz- or nevirapine-based ART on the pharmacokinetic exposure of levonorgestrel released from a subdermal implant in HIV-infected women over 24 weeks. We hypothesized that levonorgestrel concentrations would be reduced but would remain effective. Secondary objectives were to assess levonorgestrel, efavirenz, and nevirapine concentrations; HIV-related outcomes; pregnancies; and levonorgestrel-related adverse events, each over 48 weeks.

METHODS {#s2}
=======

This was a nonrandomized, open-label, parallel group, pharmacokinetic study among HIV-infected Ugandan women. All study-related procedures occurred at the Infectious Diseases Institute (IDI), Makerere University College of Health Sciences, Uganda. All study procedures followed the Declaration of Helsinki and were approved by ethics boards at the Joint Clinical Research Centre Kampala, Uganda National Council for Science and Technology, and the University of Nebraska Medical Center.

Participants {#s2a}
------------

All HIV-infected women who sought family planning services at the IDI received information about available family planning methods, including oral contraceptive pills, depo-medroxyprogesterone, intrauterine devices, condoms, and progestin-containing implants. Women aged \>18 years who planned to receive the levonorgestrel implant and were judged medically eligible for the implant \[[@CIV1001C16]\] were screened for study participation following informed consent. Women were included if they were receiving efavirenz-based ART (efavirenz 600 mg daily plus 2 NRTIs; efavirenz group), nevirapine-based ART (nevirapine 200 mg twice daily plus 2 NRTIs; nevirapine group), or were not receiving ART (ART-naive group). The ART-naive group included women with a CD4+ cell count \>500 cells/mm^3^ at screening who were not eligible for ART per Ugandan HIV guidelines at the time of enrollment \[[@CIV1001C17]\]. Women in the efavirenz or nevirapine groups received efavirenz- or nevirapine-based ART for \>30 days and had an HIV-RNA \<400 copies/mL at screening. Participants were excluded if they were pregnant, were \<30 days post-partum, or had abnormal laboratory parameters. Herbal products and medications expected to have significant interactions with study drugs were prohibited 30 days prior to entry and throughout the study \[[@CIV1001C10], [@CIV1001C14]\]. Additional hormonal contraception was prohibited.

Procedures {#s2b}
----------

Participants who met enrollment criteria returned for an entry visit (day 0) within 30 days of screening. Participants self-reported parity and marital status. Blood was collected for measurement of plasma levonorgestrel concentrations prior to implant placement. After a negative urine pregnancy test and other entry procedures were complete, a standard-dose levonorgestrel implant system (2-rod, levonorgestrel 75 mg/rod; Jadelle, Bayer, New Zealand) was placed subdermally on the interior of the upper arm by a trained study team member \[[@CIV1001C10]\].

Additional study visits occurred 1, 4, 12, 24, 36, and 48 weeks after implant placement. Blood was collected for measurement of plasma levonorgestrel, efavirenz, and nevirapine concentrations at each visit. Timing of the blood sampling for the ART groups was based on time since last ART dose: mid-efavirenz dosing interval (12--14 hours post-dose) or end of the nevirapine dosing interval (11--13 hours post-dose). If the participant missed an ART dose within the 3 prior days, the visit was rescheduled. A physical exam, documentation of new or changed medications, and a urine pregnancy test were performed at each visit. A questionnaire to detect adverse events was administered, and all adverse events were categorized by severity \[[@CIV1001C18]\]. CD4+ cell counts were abstracted from the medical record for all participants. HIV-RNA was repeated at week 48 for participants in the ART arms. Family planning counseling was provided at each visit, emphasizing the uncertainty of implant contraceptive effectiveness in combination with ART and the provision of condoms.

Pharmacokinetic Analyses {#s2c}
------------------------

Detailed methods for the levonorgestrel, efavirenz, and nevirapine assays are described in the [Supplementary Materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ1001/-/DC1). Briefly, plasma levonorgestrel concentrations were determined by reverse-phase high-performance liquid chromatography (HPLC) mass spectrometry (MS). The assay was validated over a calibration range of 49.6--1500 pg/mL. The interday precision was between 3.9% and 7.6%; accuracy was between −7.6% and 5.2%. Plasma concentrations of efavirenz and nevirapine were determined using HPLC assays with ultraviolet detection. The efavirenz assay was validated over a calibration range of 0.2--10.0 mg/L. The interday precision was between 2.8% and 5.3%; accuracy was between −6.4% and 7.0%. The nevirapine assay was validated over a calibration range of 0.05--16.1 mg/L. The interday precision was between 1.1% and 4.5%; accuracy was between 0.9% and 4.7%. All pharmacokinetic assays were validated in accordance with guidance from the US Food and Drug Administration (FDA) \[[@CIV1001C19]\].

Statistical Analyses {#s2d}
--------------------

To evaluate the primary outcome, 20 participants per group provided 95% power to detect a 45% difference in levonorgestrel concentrations, using an alpha level of 0.008 due to repeated measures and based on levonorgestrel interpatient variability (44% at 24 weeks) \[[@CIV1001C20]\]. This sample size allowed for 20% attrition (leaving 16 participants per group), while maintaining 90% power. Participants were included in the analysis if they met the primary endpoint at week 24.

Levonorgestrel concentrations were summarized by study visit as the geometric mean with 90% confidence interval (CI). Levonorgestrel concentrations were compared between the ART-naive group and the efavirenz or nevirapine groups as a geometric mean ratio (GMR) and 90% CI and statistically assessed using Wilcoxon rank sum. Each participant\'s concentration--time curve was analyzed using noncompartmental methods (Phoenix WinNonlin, Certara). The levonorgestrel AUC from weeks 0--24 (AUC~0--24\ weeks~) was determined using the trapezoidal rule. All safety and adverse event data were descriptively summarized. Descriptive data were compared using the Kruskal--Wallis or Wilcoxon rank sum tests for continuous data and a χ^2^ test for discrete data. All statistical analyses were conducted using IBM SPSS Statistics.

RESULTS {#s3}
=======

Between June 2013 and December 2013, 72 women were screened and 60 women enrolled, 20 participants into each study group. All participants enrolled in the efavirenz and nevirapine groups reached the 24-week primary endpoint; 3 participants in the ART-naive group did not (Figure [1](#CIV1001F1){ref-type="fig"}). Participants\' baseline characteristics are described in Table [1](#CIV1001TB1){ref-type="table"}. Overall, the median age of the study population was 31 years (interquartile range \[IQR\], 28.5--34.0), with 3 prior births (IQR, 2--4) and screening CD4+ cell count of 598 cells/mm^3^ (IQR, 509--806). Table 1.Baseline Characteristics of Participants by Study GroupCharacteristicAntiretroviral Therapy--Naive Group, n = 17Efavirenz Group, n = 20Nevirapine Group, n = 20Age (y)29.0 (26.5--33.0)31.0 (28.3--34.0)32.5 (31.0--35.8)Weight (kg)69.0 (58.5--86.5)59.5 (52.3--63.8)59.5 (54.3--69.8)Body mass index (kg/m^2^)29.5 (24.3--32.0)23.5 (20.1--26.2)24.4 (20.7--27.0)Cohabitating or married, n (%)11 (64.7)16 (80.0)13 (65.0)Prior live births3.0 (2.0--4.0)3.0 (2.3--4.0)3.0 (2.3--5.0)CD4+ cell count (mm^3^/mL)663.0 (549.0--971.5)556.5 (477.3--663.5)626.0 (399.8--857.3)Duration of time on current antiretroviral therapy regimen (months)...10.5 (6.3--37.8)30.5 (13.5--80.3)[^2] Figure 1.Flow diagram of screened and enrolled participants who reached the primary study endpoint at 24 weeks. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.

Women on ART received the same regimen for a median of 17.5 months (IQR, 8.5--55.0) and all had an HIV-RNA \<400 copies/mL at screening. In the efavirenz group, 13 (65%) of 20 participants received tenofovir--lamivudine 300/300 mg daily, the remaining 7 (35%) received zidovudine--lamivudine 300/150 mg twice daily. In the nevirapine group, 19 (95%) of 20 participants received zidovudine--lamivudine 300/150 mg twice daily and 1 (5%) participant received tenofovir--lamivudine 300/300 mg daily.

Primary Endpoint: 24-Week Levonorgestrel Concentrations {#s3a}
-------------------------------------------------------

The levonorgestrel pharmacokinetic results are provided in Table [2](#CIV1001TB2){ref-type="table"} and Figure [2](#CIV1001F2){ref-type="fig"}. In the efavirenz group, significantly lower levonorgestrel concentrations were observed by week 1 and persisted through week 24 compared with the ART-naive group (efavirenz: ART-naive 24-week GMR, 0.53; 90% CI, .50, .55). In contrast, we observed higher levonorgestrel concentrations in the nevirapine group by week 1, which persisted through week 24 compared with the ART-naive group (nevirapine: ART-naive 24-week GMR, 1.35; 90% CI, 1.29, 1.43). The AUC~0--24\ weeks~ for the efavirenz and nevirapine groups (8053 and 19 643 pg wk/mL, respectively) relative to the ART-naive group (15 168 pg wk/mL) reflect the stable difference in levonorgestrel concentrations over the first 24 weeks of use (efavirenz: ART-naive AUC~0--24\ weeks~ GMR, 0.53; 90% CI, .52, .54; *P* \< .001 and nevirapine: ART-naive AUC~0--24\ weeks~ GMR, 1.30; 90% CI, 1.25, 1.37; *P* = .08). Figure [3](#CIV1001F3){ref-type="fig"} presents the individual AUC~0--24\ weeks~ values by group. Table 2.Levonorgestrel Plasma Concentrations Over 48 WeeksStudy WeekART-Naive Group, n = 17 (pg/mL)^a^Efavirenz Group, n = 20 (pg/mL)^a^Nevirapine Group, n = 20 (pg/mL)^a^Efavirenz: ART-Naive Geometric Mean Ratio^b^*P* ValueNevirapine: ART-Naive Geometric Mean Ratio^b^*P* Value11070 (783, 1356)462 (370, 553)1369 (1123, 1615)0.43 (0.41, 0.47)\<.0011.28 (1.19, 1.43).1654667 (541, 792)359 (280, 437)866 (737, 995)0.54 (0.52, 0.55).0011.30 (1.26, 1.36).10412590 (475, 704)327 (268, 385)778 (674, 881)0.55 (0.55, 0.56).0011.32 (1.25, 1.42).08024528 (423, 633)280 (212, 348)710 (603, 818)0.53 (0.50, 0.55)\<.0011.35 (1.29, 1.43).05636618 (520, 716)279 (149, 409)656 (536, 777)0.45 (0.29, 0.57)\<.0011.06 (1.03, 1.09).70748^c^580 (477, 684)247 (209, 285)664 (551, 777)0.43 (0.42, 0.44).0021.14 (1.14, 1.16).300[^3][^4][^5][^6][^7] Figure 2.Geometric mean levonorgestrel concentration--time profiles over 48 weeks for each study group. A standard-dose levonorgestrel implant (2-rod, 75 mg/rod) was placed at time 0 for all participants. Values represent the geometric mean levonorgestrel plasma concentrations at each study visit for participants in the antiretroviral therapy (ART)--naive group (solid line with closed circle), efavirenz group (dashed line with open triangles), and nevirapine group (dashed line with closed squares). Figure 3.Individual levonorgestrel area under the concentration--time curve from week 0 through week 24 (AUC~0--24\ weeks~) for each study group. Each participant\'s AUC~0--24\ weeks~ is represented as a diamond; the median AUC~0--24\ weeks~ by study group is shown (line). The interindividual AUC~0--24\ weeks~ coefficient of variation (CV%) is as follows: antiretroviral therapy (ART)-naive group, 44.1%; efavirenz group, 43.7%; nevirapine group, 35.5%.

Secondary Endpoints: 48-Week Levonorgestrel Concentrations and Pregnancy Outcomes {#s3b}
---------------------------------------------------------------------------------

The intended duration of study follow-up was 48 weeks. In the ART-naive and nevirapine groups, 19 participants in each group completed follow-up; 1 woman in the ART-naive group initiated ART and 1 woman in the nevirapine group changed ART, both occurred between week 36 and week 48. No pregnancies were identified in either the ART-naive or nevirapine groups. The week 48 nevirapine:ART-naive levonorgestrel GMR was 1.14 (90% CI, 1.14, 1.16; Table [2](#CIV1001TB2){ref-type="table"}).

In the efavirenz group, 2 pregnancies were identified during the week 48 study visit (approximately 2 and 10 weeks post-conception). Following these serious events, the efavirenz group follow-up was halted, and all participants in the group returned for a study discontinuation visit. During these visits, a third pregnancy was identified at week 42 (approximately 2 weeks post-conception), bringing the total number of pregnancies to 3 (15%) of 20 participants in the efavirenz group. Levonorgestrel concentrations at the last study visit prior to each pregnancy (week 36 for all) were 122, 299, and 303 pg/mL. Levonorgestrel concentrations at each study visit for these participants are presented in [Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ1001/-/DC1). Eleven participants in the efavirenz group contributed results through week 48. The week 48 efavirenz:ART-naive levonorgestrel GMR was 0.43 (90% CI, .42, .44; Table [2](#CIV1001TB2){ref-type="table"}). Of the remaining 9 participants, 3 were pregnant and 6 discontinued follow-up between study week 40 and week 44.

Post hoc, we evaluated the number of participants who had levonorgestrel concentrations below the highest levonorgestrel concentration at which a pregnancy occurred in our population (303 pg/mL). Eighteen (90%) of 20 participants in the efavirenz group, none (0%) of 20 participants in the nevirapine group, and 2 (11.8%) of 17 participants in the ART-naive group had a concentration below 303 pg/mL at least once (*P* \< .001). For the 18 participants in the efavirenz group, levonorgestrel concentrations fell below 303 pg/mL by week 12 (IQR, 3.25--24.0) and remained below this threshold for the remainder of the study. In the ART-naive group, 1 participant had a concentration \<303 pg/mL at week 24; however, subsequent concentrations were above this threshold (range, 420--529 pg/mL). The second participant had intermittent concentrations ≤303 pg/mL at weeks 1, 4, and 48 (remaining visits range, 327--487 pg/mL).

Antiretroviral Concentrations and HIV Outcomes {#s3c}
----------------------------------------------

From week 1 through week 48, the geometric mean concentration of efavirenz was 2.7 mg/L (90% CI, 2.15, 3.30) and 6.5 mg/L for nevirapine (90% CI, 6.2, 6.9). Antiretroviral concentrations were not significantly different among individuals over the study period (data not shown).

No change was observed in the CD4+ cell count between baseline and week 48 (median week 48: ART-naive group, 698 cells/mm^3^; efavirenz group, 588 cells/mm^3^; nevirapine group, 598 cells/mm^3^; all *P* \> .05 within groups). In the efavirenz and nevirapine groups, HIV-RNA remained \<400 copies/mL in 39 of 40 women through their final study visit. One woman had an HIV-RNA of 17 935 copies/mL at week 48, despite reported ART adherence and nevirapine concentrations above the suggested minimum trough concentration (3 mg/L) \[[@CIV1001C21]\] at all study visits, except week 12.

Levonorgestrel-Related Adverse Events {#s3d}
-------------------------------------

Other than the pregnancies described above, adverse events that were possibly related to the implant are described in Table [3](#CIV1001TB3){ref-type="table"}. Of those, 13 (7.5%) of 173 adverse events were of moderate intensity (grade 2) and were predominately related to menstrual changes. All other adverse events were grade 1, and no drug-related adverse event was severe or resulted in implant discontinuation. Table 3.Adverse Events Reported Over 48 Weeks of Levonorgestrel Implant TherapyAdverse EventAntiretroviral Therapy--Naive Group, n = 17, n (%)Efavirenz Group, n = 20, n (%)Nevirapine Group, n = 20, n (%)Headache13 (76.5)15 (75.0)11 (55.0)Menstrual changes14 (82.4)13 (65.0)16 (80.0)Mood changes7 (41.2)11 (55.0)9 (45.0)Breast tenderness6 (35.3)6 (30.0)3 (15.0)Acne5 (29.4)6 (30.0)5 (25.0)Nausea4 (23.5)11 (55.0)5 (25.0)Implant insertion site discomfort2 (11.8)3 (15.0)5 (25.0)Total adverse eventsn = 51n = 68n = 54Grade 1^a^48 (94.1)60 (88.2)52 (96.3)Grade 2^a^3 (5.9)8 (11.8)2 (3.7)[^8][^9]

DISCUSSION {#s4}
==========

We determined that women who use a levonorgestrel-releasing contraceptive implant in combination with efavirenz-based ART had 47% lower levonorgestrel concentrations after 24 weeks, decreasing to 57% at week 48, compared with ART-naive women. Critically, these pharmacokinetic changes were associated with 3 unintended pregnancies in the efavirenz group (15% pregnancy rate) during the 48-week study, which is in contrast to the implant\'s expected \<1% failure rate over 5 years of use \[[@CIV1001C10]\]. These results provide pharmacokinetic evidence and further support for the high unintended pregnancy rate (12.4%) that was observed retrospectively among 121 women in Swaziland who received efavirenz-based ART with a levonorgestrel-releasing implant \[[@CIV1001C13]\]. In addition, our data are consistent with a pharmacokinetic study of ART with the only other progestin-releasing subdermal implant, etonogestrel, in that etonogestrel plasma concentrations were 63% lower among HIV-infected women who received efavirenz-based ART \[[@CIV1001C22]\]. In a recent retrospective cohort from Kenya, a 3-fold higher pregnancy risk was observed in implant users (either levonorgestrel- or etonogestrel-containing) who received efavirenz-based ART compared with nevirapine-based ART (adjusted rate ratio, 3.0 \[1.3--4.6\]) \[[@CIV1001C23]\]. Notably, the pregnancy rate in patients who received implants plus efavirenz-based ART in the Kenya cohort (unadjusted pregnancies, 3.3 per 100 person-years) was lower compared with both our results and those reported from Swaziland \[[@CIV1001C13], [@CIV1001C23]\]. Similarly, 6 published case reports describe etonogestrel implant failures in women who received efavirenz-based ART \[[@CIV1001C24]--[@CIV1001C27]\].

In contrast, women in our nevirapine group had 35% higher levonorgestrel concentrations after 24 weeks, and 14% higher after 48 weeks, compared with the ART-naive group. We observed no pregnancy or excess adverse events, supporting the effectiveness of levonorgestrel implants in combination with nevirapine-based ART. Although both are CYP3A enzyme inducers, differences in the drug--drug interaction potential of efavirenz and nevirapine have been observed \[[@CIV1001C11], [@CIV1001C12]\]. One possible explanation of higher levonorgestrel concentrations may be the study participants\' body weight. Prior studies demonstrate an inverse association between levonorgestrel concentrations and body weight; women weighing \<50 kg maintained levonorgestrel concentrations 43%--50% higher than women weighing \>70 kg \[[@CIV1001C20], [@CIV1001C28], [@CIV1001C29]\]. Although the difference in body weight between the nevirapine and ART-naive groups was not statistically different, the nevirapine group had more women with lower body weights (see Table [1](#CIV1001TB1){ref-type="table"}).

We are the first to describe progestin concentrations prior to conception among women who became pregnant while using an implant due to a drug--drug interaction. One other study characterized levonorgestrel concentrations prior to pregnancy during an extended-use study of the implant over 7 years, 2 years beyond its intended duration of use \[[@CIV1001C29]\]. Sivin and colleagues determined that no pregnancies occurred when levonorgestrel concentrations were maintained above 180 pg/mL \[[@CIV1001C29]\]. In contrast, 2 pregnancies occurred in our participants at concentrations above this previously observed efficacy threshold, that is, 303 and 299 pg/mL, measured approximately 2 and 10 weeks prior to conception ([Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ1001/-/DC1)). The reason for this difference is unclear, but a potential explanation is differences in laboratory methods for quantitation of levonorgestrel: HPLC-MS vs radioimmunoassay \[[@CIV1001C29]\].

Integrated guidelines for family planning and HIV suggest that contraceptive implants can be used for HIV-infected women receiving efavirenz-based ART \[[@CIV1001C30]\]. However, our data suggest that efavirenz-based ART reduces the contraceptive efficacy of the levonorgestrel implant. Although both levonorgestrel implants and efavirenz have been available in LMICs over the past decade, the impact of this detrimental drug--drug interaction may not have been identified because, until recently, efavirenz was not widely prescribed among women of childbearing potential due to concerns for teratogenicity. Furthermore, because many HIV treatment centers do not have integrated family planning services, women may obtain levonorgestrel implants from other providers, and an unintended pregnancy could go unrecognized by HIV caregivers. This highlights the importance of integrated, comprehensive care of HIV-infected persons, as well as multidisciplinary collaboration to disseminate findings \[[@CIV1001C31]\].

Our study has limitations related to its design. It was an open label, nonrandomized, clinical pharmacokinetic investigation of women already planning to receive the levonorgestrel implant. Therefore, baseline differences exist between study groups. We did not assess participants' sexual activity, and the study was not designed to evaluate the contraceptive effectiveness of the levonorgestrel implant in combination with ART. Therefore, measures of contraceptive effectiveness such as detection of ovulation or changes in the cervical--vaginal lining were not included. Despite this, our results support an exposure--response relationship, and pharmacokinetic data are an FDA-accepted method to establish the impact of a drug--drug interaction \[[@CIV1001C32]\]. Finally, we cannot compare our results with the contraception failure rate of other methods in combination with ART.

We describe suboptimal pharmacokinetic exposure when the levonorgestrel implant is combined with efavirenz-based ART, but not with nevirapine-based ART. The increased risk of unintended pregnancy in women who received the levonorgestrel implant and efavirenz-based ART is of critical public health importance, given the ongoing scale-up of both contraceptive implants \[[@CIV1001C33]\] and efavirenz-based ART throughout LMICs and the resultant decreased use of nevirapine-based ART in many countries \[[@CIV1001C6], [@CIV1001C8]\]. Policymakers will need to assess the risk--benefit of the levonorgestrel implant combined with efavirenz-based ART in the context of alternative contraceptive failure rates and available ART options in LMICs. Given the increased risk of unintended pregnancy among HIV-infected women using the levonorgestrel implant with efavirenz-based ART, alternative strategies for long-acting contraceptive agents are urgently needed.

Supplementary Data {#s5}
==================

[Supplementary materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ1001/-/DC1) are available at <http://cid.oxfordjournals.org>. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
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